George joined Horizon Pharma in 2008 as a consultant and transitioned to a full-time employee in April 2015. He currently serves as executive vice president, primary care business unit where he is tasked with leading the forward-looking strategy, as well as establishing operational goals for the team. He has more than 20 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rheumatology/autoimmune (HUMIRA), primary care (CELEBREX), orthopedic, diabetes (BYETTA), anti-infectives and cardiovascular spaces. This includes 10 product launches in roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott Immunology (now AbbVie), and Amylin Pharmaceuticals. Most recently, George served as president and chief executive officer of a privately held technology company.

George joined Horizon Pharma in 2008 as a consultant and transitioned to a full-time employee in April 2015. He currently serves as executive vice president, primary care business unit where he is tasked with leading the forward-looking strategy, as well as establishing operational goals for the team. He has more than 20 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rheumatology/autoimmune (HUMIRA), primary care (CELEBREX), orthopedic, diabetes (BYETTA), anti-infectives and cardiovascular spaces. This includes 10 product launches in roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott Immunology (now AbbVie), and Amylin Pharmaceuticals. Most recently, George served as president and chief executive officer of a privately held technology company.